NASDAQ:CYTK - Cytokinetics Stock Price, Price Target & More

Get Started

$8.80 +0.05 (+0.57 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$8.75

Today's Range$8.68 - $8.95

52-Week Range$6.75 - $15.95

Volume122,508 shs

Average Volume340,764 shs

Market Capitalization$471.52 million

P/E Ratio-3.40

Dividend YieldN/A

Beta1.13

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CYTK

CUSIPN/A

Webwww.cytokinetics.com

Phone650-624-3000

Debt

Debt-to-Equity Ratio0.32

Current Ratio7.07

Quick Ratio7.07

Price-To-Earnings

Trailing P/E Ratio-3.40

Forward P/E Ratio-4.25

P/E GrowthN/A

Sales & Book Value

Annual Sales$13.37 million

Price / Sales35.67

Cash FlowN/A

Price / CashN/A

Book Value$1.84 per share

Price / Book4.78

Profitability

EPS (Most Recent Fiscal Year)($2.59)

Net Income$-127,790,000.00

Net Margins-172.27%

Return on Equity-99.50%

Return on Assets-42.59%

Miscellaneous

Employees137

Outstanding Shares54,200,000

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics (NASDAQ:CYTK) posted its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.06. The biopharmaceutical company earned $5.27 million during the quarter, compared to the consensus estimate of $5.50 million. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 99.50%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

8 brokerages have issued 12-month price targets for Cytokinetics' shares. Their forecasts range from $10.00 to $24.00. On average, they expect Cytokinetics' stock price to reach $15.75 in the next year. View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:

1. Cantor Fitzgerald analysts commented, "Robert Califf, M.D. has joined CYTK’s Board of Directors (BoD), adding his expertise in cardiovascular and regulatory domains, we believe." (2/12/2018)
2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)

Who are some of Cytokinetics' key competitors?

Some companies that are related to Cytokinetics include Enanta Pharmaceuticals (ENTA), Phibro Animal Health (PAHC), Prestige Brands (PBH), MyoKardia (MYOK), Madrigal Pharmaceuticals (MDGL), Akorn (AKRX), Motif (MTFB), G1 Therapeutics (GTHX), Cambrex (CBM), ARMO BioSciences (ARMO), Zogenix (ZGNX), Innoviva (INVA), Endo International (ENDP), Pacira Pharmaceuticals (PCRX) and ImmunoGen (IMGN).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:

Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)

Has Cytokinetics been receiving favorable news coverage?

Media coverage about CYTK stock has trended somewhat positive this week, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytokinetics earned a news impact score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 44.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.44%), Wasatch Advisors Inc. (3.26%), Pinnacle Associates Ltd. (1.64%), Citigroup Inc. (1.43%), Principal Financial Group Inc. (0.73%) and Principal Financial Group Inc. (0.74%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc. and American International Group Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Millennium Management LLC, Employees Retirement System of Texas, A.R.T. Advisors LLC, UBS Group AG, JPMorgan Chase & Co., BlackRock Inc. and DRW Securities LLC. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $8.80.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $471.52 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]

MarketBeat Community Rating for Cytokinetics (CYTK)

Community Ranking:		3.8 out of 5 ( )
Outperform Votes:		412 (Vote Outperform)
Underperform Votes:		133 (Vote Underperform)
Total Votes:		545

MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Cytokinetics (NASDAQ:CYTK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Cytokinetics in the last 12 months. Their average twelve-month price target is $15.75, suggesting that the stock has a possible upside of 78.98%. The high price target for CYTK is $24.00 and the low price target for CYTK is $10.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.88	2.88	2.89	2.90
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$15.75	$15.75	$16.7778	$17.90
Price Target Upside:	78.98% upside	118.75% upside	116.49% upside	116.97% upside

Cytokinetics (NASDAQ:CYTK) Consensus Price Target History

Price Target History for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/27/2018	HC Wainwright	Reiterated Rating	Buy	$20.00	High
4/24/2018	Cantor Fitzgerald	Set Price Target	Hold	$10.00	Low
2/21/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $18.00	High
2/20/2018	Cowen	Reiterated Rating	Buy	$11.00	Medium
11/29/2017	Needham & Company LLC	Downgrade	Strong-Buy ➝ Buy	$22.00 ➝ $12.00	Low
11/21/2017	JMP Securities	Reiterated Rating	Outperform	$17.00 ➝ $13.00	N/A
11/21/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$18.00	N/A
10/6/2017	Seaport Global Securities	Reiterated Rating	Buy	$24.00	N/A
3/23/2017	Rodman & Renshaw	Reiterated Rating	Buy	$25.00	Medium
2/17/2017	FBR & Co	Reiterated Rating	Outperform	$24.00	N/A
10/28/2016	Roth Capital	Set Price Target	Buy	$22.00	N/A

(Data available from 5/25/2016 forward)

Cytokinetics (NASDAQ:CYTK) Earnings History and Estimates Chart

Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS

Cytokinetics (NASDAQ CYTK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/31/2018		($0.52)					N/A
4/26/2018	Q1 2018	($0.50)	($0.56)	$5.50 million	$5.27 million	View	N/A
2/15/2018	Q4 2017	($0.71)	($0.75)	$4.83 million	($0.02) million	View	Listen
10/26/2017	Q3 2017	($0.64)	($0.60)	$5.35 million	$6.18 million	View	N/A
8/2/2017	Q2 2017	($0.5730)	($0.60)	$5.28 million	$3.05 million	View	Listen
4/27/2017	Q1 2017	($0.11)	($0.62)	$5.08 million	$4.15 million	View	N/A
2/16/2017	Q416	($0.39)	$0.1640	$14.10 million	$33.14 million	View	Listen
10/27/2016	Q3	($0.2730)	$0.74	$6.67 million	$59.05 million	View	Listen
7/28/2016	Q2	($0.2750)	($0.29)	$7.80 million	$5.80 million	View	Listen
4/28/2016	Q1	($0.37)	($0.31)	$8.14 million	$8.42 million	View	Listen
2/16/2016	Q415	($0.32)	($0.24)	$10.49 million	$9.80 million	View	Listen
10/29/2015	Q315	($0.30)	($0.23)	$11.24 million	$7.90 million	View	Listen
7/29/2015	Q2	($0.28)	($0.27)	$4.00 million	$6.54 million	View	Listen
4/30/2015	Q1	($0.08)	($0.23)	$10.10 million	$4.40 million	View	Listen
2/12/2015	Q4	($0.17)	$0.23	$10.80 million	$21.80 million	View	Listen
10/30/2014	Q3	($0.27)	($0.16)	$6.50 million	$9.42 million	View	Listen
7/30/2014	Q2	($0.32)	($0.23)	$7.01 million	$7.80 million	View	Listen
5/6/2014	Q1	($0.34)	($0.27)	$7.69 million	$8.00 million	View	Listen
2/6/2014	Q4	($0.08)	$0.21	$19.14 million	$24.30 million	View	Listen
10/30/2013	Q3 2013	($0.09)	($0.43)	$15.77 million	$4.47 million	View	N/A
7/31/2013	Q2 2013	($0.55)	($0.58)	$4.36 million	$1.01 million	View	N/A
4/30/2013	Q1 2013	($0.54)	($0.54)	$0.92 million	$0.82 million	View	N/A
2/5/2013	Q4 2012	($0.60)	($0.42)			View	N/A
10/30/2012	Q3 2012	($0.60)	($0.42)			View	N/A
7/31/2012	Q2 2012	($0.72)	($0.78)			View	N/A
4/26/2012	Q1 2012	($0.84)	($0.78)			View	N/A
2/2/2012	Q4 2011	($0.78)	($0.88)			View	N/A
10/27/2011	Q3 2011	($1.14)	($0.88)			View	N/A
7/28/2011	Q2 2011	($0.66)	($1.39)			View	N/A
4/27/2011	Q1 2011	($1.14)	($1.08)			View	N/A
2/14/2011	Q4 2010	($1.32)	($1.01)			View	N/A
10/28/2010	Q3 2010	($1.26)	($1.15)			View	N/A
7/28/2010	Q2 2010	($1.20)	($1.19)			View	N/A
4/29/2010	Q1 2010	($1.20)	($1.18)			View	N/A
2/3/2010	Q4 2009	($1.32)	($1.20)			View	N/A
10/28/2009	Q3 2009	($1.32)	($0.82)			View	N/A
7/29/2009	Q2 2009	$3.06	$5.90			View	N/A
4/30/2009	Q1 2009	($1.20)	($1.24)			View	N/A
2/10/2009	Q4 2008	($2.28)	($1.31)			View	N/A
10/30/2008	Q3 2008	($2.16)	($1.67)			View	N/A
7/31/2008	Q2 2008	($2.04)	($1.87)			View	N/A
4/29/2008	Q1 2008	($1.92)	($1.69)			View	N/A
1/31/2008	Q4 2007	($2.52)	($1.61)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Cytokinetics (NASDAQ:CYTK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 68.07%

Insider Trading History for Cytokinetics (NASDAQ:CYTK)

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/4/2018	Robert I Blum	CEO	Sell	4,000	$8.38	$33,520.00	183,722
4/5/2018	Robert I Blum	CEO	Sell	4,000	$7.52	$30,080.00	182,701
1/16/2018	Caryn Gordon Mcdowell	Insider	Sell	2,709	$9.00	$24,381.00	15,077
11/2/2017	Caryn Gordon Mcdowell	Insider	Sell	4,260	$12.94	$55,124.40	17,982
11/1/2017	Fady Ibraham Malik	EVP	Sell	7,321	$13.39	$98,028.19	47,540
11/1/2017	Robert I Blum	CEO	Sell	5,000	$13.51	$67,550.00	70,180
10/6/2017	Caryn Gordon Mcdowell	Insider	Sell	13,181	$15.49	$204,173.69
10/2/2017	Robert I Blum	CEO	Sell	5,000	$14.59	$72,950.00
9/6/2017	Caryn Gordon Mcdowell	Insider	Sell	10,131	$14.60	$147,912.60	19,801
9/1/2017	Robert I Blum	CEO	Sell	5,000	$14.71	$73,550.00	79,785
8/31/2017	Bradley Paul Morgan	SVP	Sell	118,330	$15.00	$1,774,950.00	63,107
8/31/2017	Santo J Costa	Director	Sell	5,000	$15.00	$75,000.00	5,000
8/29/2017	Santo J Costa	Director	Sell	5,000	$14.00	$70,000.00	5,000
8/8/2017	Caryn Gordon Mcdowell	Insider	Sell	11,348	$12.47	$141,509.56	21,570
8/1/2017	Robert I Blum	CEO	Sell	5,000	$13.79	$68,950.00	84,785
7/3/2017	Robert I Blum	CEO	Sell	5,000	$12.14	$60,700.00	88,385
6/1/2017	Robert I Blum	CEO	Sell	5,000	$13.62	$68,100.00	94,785
12/29/2016	Fady Ibraham Malik	EVP	Sell	5,633	$12.36	$69,623.88	3,361
8/31/2015	L Patrick Gage	Director	Buy	1,000	$6.95	$6,950.00	30,000
8/20/2015	L Patrick Gage	Director	Buy	10,000	$6.55	$65,500.00	30,000
5/6/2015	L Patrick Gage	Director	Buy	10,000	$5.71	$57,100.00
3/11/2015	Andrew A Wolff	CMO	Sell	21,875	$7.80	$170,625.00
12/30/2014	Fady Ibraham Malik	SVP	Sell	21,630	$6.73	$145,569.90
5/9/2014	L Patrick Gage	Director	Buy	10,850	$4.09	$44,376.50	10,000
2/25/2014	Eastern Capital Ltd	major shareholder	Buy	500,000	$8.00	$4,000,000.00	2,883,845

(Data available from 1/1/2013 forward)

Cytokinetics (NASDAQ CYTK) News Headlines

Source:

Date	Headline
	Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA finance.yahoo.com - May 17 at 3:10 PM
	Zacks: Brokerages Expect Cytokinetics (CYTK) Will Post Quarterly Sales of $5.57 Million www.americanbankingnews.com - May 12 at 2:06 AM
	Cytokinetics to Hold Annual Meeting of Stockholders finance.yahoo.com - May 11 at 5:18 AM
	Zacks: Brokerages Anticipate Cytokinetics (CYTK) to Announce -$0.51 Earnings Per Share www.americanbankingnews.com - May 10 at 7:19 PM
	Cytokinetics (CYTK) Given Average Recommendation of "Buy" by Analysts www.americanbankingnews.com - May 7 at 1:49 PM
	Robert I. Blum Sells 4,000 Shares of Cytokinetics (CYTK) Stock www.americanbankingnews.com - May 4 at 8:15 PM
	Brokers Issue Forecasts for Cytokinetics' FY2018 Earnings (CYTK) www.americanbankingnews.com - May 2 at 9:42 AM
	Cytokinetics (CYTK) Upgraded to Hold at BidaskClub www.americanbankingnews.com - April 28 at 8:34 AM
	Cytokinetics (CYTK) Lifted to Hold at ValuEngine www.americanbankingnews.com - April 27 at 10:52 PM
	Cytokinetics (CYTK) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS www.americanbankingnews.com - April 27 at 4:12 PM
	Edited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMT finance.yahoo.com - April 27 at 3:02 PM
	Cytokinetics (CYTK) Given a $20.00 Price Target at HC Wainwright www.americanbankingnews.com - April 27 at 12:34 PM
	BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.56 www.reuters.com - April 27 at 5:11 AM
	Cytokinetics' (CYTK) CEO Robert Blum on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 27 at 5:11 AM
	Cytokinetics, Inc. Reports First Quarter 2018 Financial Results finance.yahoo.com - April 27 at 5:11 AM
	Cytokinetics: 1Q Earnings Snapshot finance.yahoo.com - April 27 at 5:11 AM
	Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value? finance.yahoo.com - April 26 at 3:02 PM
	Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal ... globenewswire.com - April 24 at 3:10 PM
	Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference finance.yahoo.com - April 24 at 3:10 PM
	Cantor Fitzgerald Analysts Give Cytokinetics (CYTK) a $10.00 Price Target www.americanbankingnews.com - April 24 at 10:28 AM
	Cytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 3:44 AM
	Cytokinetics (CYTK) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 16 at 10:54 AM
	Cytokinetics (CYTK) Given a $26.00 Price Target at HC Wainwright www.americanbankingnews.com - April 13 at 7:15 PM
	Cytokinetics to Announce First Quarter Results on April 26, 2018 globenewswire.com - April 13 at 5:03 AM
	Cytokinetics to Announce First Quarter Results on April 26, 2018 finance.yahoo.com - April 13 at 5:03 AM
	Cytokinetics (CYTK) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - April 12 at 1:41 PM
	Insider Selling: Cytokinetics, Inc. (CYTK) CEO Sells 4,000 Shares of Stock www.americanbankingnews.com - April 6 at 7:33 PM
	Cytokinetics (CYTK) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 5 at 2:09 PM
	Cytokinetics (CYTK) Downgraded by TheStreet www.americanbankingnews.com - April 2 at 9:42 PM
	Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT finance.yahoo.com - April 1 at 5:00 AM
	Cytokinetics (CYTK) Cut to "Strong Sell" at ValuEngine www.americanbankingnews.com - March 29 at 11:18 PM
	Cytokinetics (CYTK) Rating Increased to Sell at BidaskClub www.americanbankingnews.com - March 24 at 1:11 PM
	Cytokinetics, Inc. (CYTK) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 18 at 1:48 PM
	Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day finance.yahoo.com - February 28 at 3:13 PM
	Cytokinetics (CYTK) PT Raised to $18.00 www.americanbankingnews.com - February 21 at 5:30 PM
	Cytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - February 21 at 2:31 PM
	Cytokinetics (CYTK) Earns Buy Rating from Cowen www.americanbankingnews.com - February 20 at 8:26 PM
	Cytokinetics Sees Unusually Large Options Volume (CYTK) www.americanbankingnews.com - February 20 at 6:56 AM
	Cytokinetics (CYTK) Announces Earnings Results, Misses Estimates By $0.04 EPS www.americanbankingnews.com - February 16 at 11:40 AM
	Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release) globenewswire.com - February 16 at 5:10 AM
	Cytokinetics reports 4Q loss finance.yahoo.com - February 16 at 5:10 AM
	Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results finance.yahoo.com - February 16 at 5:10 AM
	Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million www.americanbankingnews.com - February 16 at 3:46 AM
	Cytokinetics Earnings Outlook - Benzinga www.benzinga.com - February 15 at 3:10 PM
	Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release) globenewswire.com - February 15 at 5:10 AM
	Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference finance.yahoo.com - February 15 at 5:10 AM
	Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share www.americanbankingnews.com - February 14 at 5:16 PM
	Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release) www.globenewswire.com - February 14 at 3:09 PM
	Cytokinetics (CYTK) Names Robert Califf to Board of Directors www.streetinsider.com - February 13 at 3:07 PM
	Cytokinetics' (CYTK) Hold Rating Reiterated at Cantor Fitzgerald www.americanbankingnews.com - February 12 at 4:18 PM

Cytokinetics (NASDAQ:CYTK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement

Cytokinetics (NASDAQ CYTK) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff